These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 28189497)
1. Correlates of Triple Negative Breast Cancer and Chemotherapy Patterns in Black and White Women With Breast Cancer. Sheppard VB; Cavalli LR; Dash C; Kanaan YM; Dilawari AA; Horton S; Makambi KH Clin Breast Cancer; 2017 Jun; 17(3):232-238. PubMed ID: 28189497 [TBL] [Abstract][Full Text] [Related]
2. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753 [TBL] [Abstract][Full Text] [Related]
3. Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Ma H; Ursin G; Xu X; Lee E; Togawa K; Duan L; Lu Y; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L Breast Cancer Res; 2017 Jan; 19(1):6. PubMed ID: 28086982 [TBL] [Abstract][Full Text] [Related]
4. Does race predict survival for women with invasive breast cancer? Walsh SM; Zabor EC; Stempel M; Morrow M; Gemignani ML Cancer; 2019 Sep; 125(18):3139-3146. PubMed ID: 31206623 [TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer. Jiagge E; Jibril AS; Chitale D; Bensenhaver JM; Awuah B; Hoenerhoff M; Adjei E; Bekele M; Abebe E; Nathanson SD; Gyan K; Salem B; Oppong J; Aitpillah F; Kyei I; Bonsu EO; Proctor E; Merajver SD; Wicha M; Stark A; Newman LA Ann Surg Oncol; 2016 Nov; 23(12):3843-3849. PubMed ID: 27469125 [TBL] [Abstract][Full Text] [Related]
6. Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy. Woriax HE; Thomas SM; Plichta JK; Rosenberger LH; Botty van den Bruele A; Chiba A; Hwang ES; DiNome ML J Clin Oncol; 2024 May; 42(14):1635-1645. PubMed ID: 38394476 [TBL] [Abstract][Full Text] [Related]
7. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women. Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715 [TBL] [Abstract][Full Text] [Related]
8. Alcohol intake and invasive breast cancer risk by molecular subtype and race in the Carolina Breast Cancer Study. Williams LA; Olshan AF; Tse CK; Bell ME; Troester MA Cancer Causes Control; 2016 Feb; 27(2):259-69. PubMed ID: 26705260 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes. Murphy BL; Day CN; Hoskin TL; Habermann EB; Boughey JC Ann Surg Oncol; 2018 Aug; 25(8):2241-2248. PubMed ID: 29786125 [TBL] [Abstract][Full Text] [Related]
10. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484 [TBL] [Abstract][Full Text] [Related]
11. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt. Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605 [TBL] [Abstract][Full Text] [Related]
12. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215 [TBL] [Abstract][Full Text] [Related]
13. Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014. Scott LC; Mobley LR; Kuo TM; Il'yasova D Cancer; 2019 Oct; 125(19):3412-3417. PubMed ID: 31282032 [TBL] [Abstract][Full Text] [Related]
14. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182 [TBL] [Abstract][Full Text] [Related]
15. Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy. Wright JL; Reis IM; Zhao W; Panoff JE; Takita C; Sujoy V; Gomez CR; Jorda M; Franceschi D; Hurley J Breast; 2012 Jun; 21(3):276-83. PubMed ID: 22178596 [TBL] [Abstract][Full Text] [Related]
16. Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study. Felix AS; Cohn DE; Brasky TM; Zaino R; Park K; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel CI; Boggess JF; Pearl ML; Ioffe OB; Randall ME; Brinton LA Am J Obstet Gynecol; 2018 Nov; 219(5):459.e1-459.e11. PubMed ID: 30096321 [TBL] [Abstract][Full Text] [Related]
17. Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea. Lee JS; Oh M; ; Clin Breast Cancer; 2014 Dec; 14(6):426-34. PubMed ID: 25034438 [TBL] [Abstract][Full Text] [Related]
18. PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy. Guo S; Loibl S; von Minckwitz G; Darb-Esfahani S; Lederer B; Denkert C Cancer Res Treat; 2020 Jul; 52(3):689-696. PubMed ID: 32019278 [TBL] [Abstract][Full Text] [Related]
19. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]